



suyono suyono <suyono@upstegal.ac.id>

Decision on submission to Heliyon

1 message

Heliyon <em@editorialmanager.com>

Wed, Jan 15, 2025 at 11:56 PM

Reply-To: Heliyon <heliyonjournal@elsevier.com>

To: Suyono Suyono <suyono@upstegal.ac.id>

Manuscript Number: %MANUSCRIPT_NUMBER%
Innovative Silvofishery Model in Restored Mangrove Forests: A 10-Year Assessment
Heliyon

Dear Dr Suyono,

I am pleased to inform you that your paper has now been accepted for publication in Heliyon

Your accepted manuscript will be forwarded to our production department for further processing. A proof will be generated for your review. For further details, please refer to the provided link: [Proofs](#)

Meanwhile, you will be asked to complete a number of online forms required for publication. If we need additional information from you during the production process, we will contact you directly.

Thank you for submitting your work to Heliyon. We hope you consider us again for future submissions.

Kind regards,
Heliyon

Gowsika Rengaraj

Editorial Section Manager

Follow us on our social media channels.

[Heliyon](#)

[Heliyon \(@HeliyonJournal\) / X](#)

[Instagram \(@cellpress\)](#)

<https://www.linkedin.com/company/cell-press/>

Wechat: CellPress细胞科学

[Sina Visitor System](#)

Have questions or need assistance?

For further assistance, please visit our customer service site: <http://help.elsevier.com/app/answers/list/p/9435/>. Here you can search for solutions on a range of topics, find answers to

frequently asked questions, and learn more about Editorial Manager via interactive tutorials. You can also talk 24/5 to our customer support team by phone and 24/7 by live chat and email.

At Elsevier, we want to help all our authors to stay safe when publishing. Please be aware of fraudulent messages requesting money in return for the publication of your paper. If you are publishing open access with Elsevier, bear in mind that we will never request payment before the paper has been accepted. We have prepared some guidelines (<https://www.elsevier.com/connect/authors-update/seven-top-tips-on-stopping-apc-scams>) that you may find helpful, including a short video on Identifying fake acceptance letters (<https://www.youtube.com/watch?v=o5l8thD9XtE>). Please remember that you can contact Elsevier s Researcher Support team (<https://service.elsevier.com/app/home/supporthub/publishing/>) at any time if you have questions about your manuscript, and you can log into Editorial Manager to check the status of your manuscript (https://service.elsevier.com/app/answers/detail/a_id/29155/c/10530/supporthub/publishing/kw/status/).

#AU_HELIYON#

To ensure this email reaches the intended recipient, please do not delete the above code

In compliance with data protection regulations, you may request that we remove your personal registration details at any time. ([Remove my information/details](#)). Please contact the publication office if you have any questions.

Date: Jan 06, 2025
To: "Suyono Suyono" suyono@upstegal.ac.id
From: "Heliyon" heliyonjournal@elsevier.com
Subject: Decision on submission HELIYON-D-23-26611R1 to Heliyon

Manuscript Number: %MANUSCRIPT_NUMBER%

Title: Innovative Silvofishery Model in Restored Mangrove Forests: A 10-Year Assessment
Journal: Heliyon

Dear Dr Suyono,

Thank you for submitting your manuscript to Heliyon.

We have now received all of the editor and reviewer comments on your recent submission to Heliyon. Your paper will become acceptable for publication after implementation of the important formatting and/or administrative changes outlined below. Please note that if the resubmitted manuscript file does not address these issues, we may need to reject your manuscript.

Comments for authors to address:

We have identified changes to your Authorship list made after the initial round of review which we judge are not appropriate in this case. Please re-instate your original Authorship list upon re-submission of your manuscript. If you do not do this we may be forced to reconsider our decision for your submission and issue a reject decision.

Please add a Data and Code Availability statement in your manuscript file. Note that this information will be available alongside your article upon publication. You may use one of the following formats:

- [Standardized datatype] data have been deposited at [datatype-specific repository (URL to the repository)] with accession numbers [Database IDs].
- Data included in the article/supplementary material is referenced in the article.
- No new data was generated for the research described in the article.
- Data will be made available on request. For requesting data, please write to the corresponding author.

If not already included, please add a 'Data availability statement' in your manuscript along with the name of the repository and the accession number if applicable. The statement should be located right before the 'References' section.

Kindly review our ethics requirements and select all the relevant statements from our ethics declarations list (available here: <https://www.cell.com/heliyon/guide-for-authors>) to form a comprehensive ethics statement. This should be included in the declarations section at the end of your manuscript.

Furthermore, please ensure that the references in your manuscript are in a numbered format, if not already. To avoid unnecessary delays in the publication of your manuscript, please do not make any additional changes apart from those requested during this revision.

To submit your revised manuscript, please log in as an author at <https://www.editorialmanager.com/heliyon/>, and navigate to the "Submissions Needing Revision" folder under the Author Main Menu.

When submitting your revised manuscript, please ensure you upload only your most recent and up-to-date manuscript using the "Revised Manuscript File – with highlights (no tracked changes)." Use highlighting to indicate the revisions made in response to reviewer and editor comments. **To ensure a smooth production process, please do not include any tracked changes in your manuscript file. This allows the production team to process your manuscript efficiently and minimises the risk of delays or miscommunication during the typesetting stage."**

If you need additional time to address the concerns that came up in the review process, please let us know so we can discuss a plan for moving your paper forward.

We encourage authors of original research papers to share the research objects – including raw data, methods, protocols, software, hardware and other outputs – associated with their paper. More information on how our open access Research Elements journals can help you do this is available at [https://www.elsevier.com/authors/tools-and-resources/research-elements-journals](https://www.elsevier.com/authors/tools-and-resources/research-elements-journals?dgcid=ec_em_research_elements_email)

Kind regards,
Heliyon

Gowsika Rengaraj

Editorial Section Manager

Embargo

Embargos are not automatically set for papers published in Heliyon. Papers appear online a few days after acceptance. ¹ ³ ^{quest a} media embargo and/or publication on a specific date, please reach out to the Heliyon team (info@heliyon.com) and cc our press office (press@cell.com) as soon as possible and we will do our best to accommodate your request. For any other questions about publicity, please contact our press office.

More information and support










FAQ: [How do I revise my submission in Editorial Manager?](#)



← Submissions with an Editorial Office Decision for Author

Page: 1 of 1 (1 total completed submissions)

Results per page 10

Action 		Manuscript Number 	Title 	Initial Date Submitted 	Status Date 	Current Status 	Date Final Disposition Set 	Final Disposition 
Action Links		HELIYON-D-23-26611	Innovative Silvofishery Model in Restored Mangrove Forests: A 10-Year Assessment	Jun 28, 2023	Jan 15, 2025	Completed - Accept	Jan 15, 2025	Accept

Page: 1 of 1 (1 total completed submissions)

Results per page 10





99+



1 of 543

Mail

Chat

Meet

ELSEVIER

Track your article!

Paper Accepted in the Editorial system → Paper Received in Production → Proofs are being created → Proofs are Ready for Approval → Corrections to the Proof Submitted → Paper is Finalised → Issue is Finalised


Title: *Innovative Silvofishery Model in Restored Mangrove Forests: A 10-Year Assessment*
Reference: *HLY_e42043*

Dear Dr Suyono,

We're looking forward to your article *Innovative Silvofishery Model in Restored Mangrove Forests: A 10-Year Assessment* soon being published in Heliyon.

You can follow your article's journey throughout the publication process by using our article tracking service.

<https://authors.elsevier.com/tracking/article/details.do?aid=42043&jid=HLY&surname=Suy>



Publishing Agreement

Elsevier Ltd

Innovative Silvofishery Model in Restored Mangrove Forests: A 10-Year Assessment

Corresponding author	Dr Suyono Suyono
E-mail address	suyono@upstegal.ac.id
Journal	Heliyon
Article number	e42043
Our reference	HLY_e42043
PII	S2405-8440(25)00423-2

Your Status

- I am the sole author of the manuscript
- I am signing on behalf of the corresponding author.
 - **Name/Job title/Company:** Suyono, Senior Lecturer, Pancasakti University Tegal
 - **E-mail address:** suyono@upstegal.ac.id

The License Agreement

The authors have created the article identified above which, together with any tables, illustrations or other material submitted for publication as part of the article, is referred to in this License Agreement as the “Article”. The authors wish Elsevier Ltd to publish and distribute the Article and to protect the rights granted under this License Agreement. To enable Elsevier Ltd to do so, each author grants Elsevier Ltd the rights set out in this License Agreement.

Copyright ownership of the Article

Each author retains their copyright in the Article. Except for the license of the Article as set out below, this License Agreement does not transfer any rights in patents, trademarks or other intellectual property rights to Elsevier Ltd. Elsevier Ltd shall publish and distribute the Article with an appropriate copyright notice.

Authors’ rights in the Article

Subject to the terms of this License Agreement, each author retains the right to re-use the Article for their own commercial and non-commercial purposes, as well as to create derivative works, without permission from Elsevier Ltd or payment to Elsevier Ltd. Each author shall, in connection with any such re-use of the Article, fully acknowledge and attribute the original publication of the Article.

Nothing in this License Agreement shall limit the re-use rights of authors, except in relation to the grant of rights to third parties for commercial purposes, as set out below.

By way of illustrative examples of re-use, each author retains the right to:

- make copies of the Article (or part of the Article) to promote companies or products they own, whether or not such promotion is commercial;
- include the Article in a thesis or dissertation;
- extend the Article to a book, include the Article in a subsequent compilation of their own work, or re-use portions, excerpts, and their own figures, tables and images from the Article in their own new works (which in each case may be published with Elsevier or with a third party commercial or non-commercial publisher, at the author’s discretion);
- use and share the Article for scholarly purposes, including for classroom teaching, in conferences, and for non-commercial Massive Open Online Courses;

- create translations of the Article and authorize others to do so for non-commercial scholarly collaborations and sharing;
- publicly share the Article on non-commercial websites, such as institutional repositories; and
- post the Article on commercial scholarly collaboration websites for the purpose only of hosting by those websites.

Each author agrees not to license any third party to exercise all or any of the rights in the Article or any part of the Article for commercial purposes. Each author agrees to promptly refer any third party requests for a license of such rights to Elsevier Ltd.

Each author acknowledges the importance of the integrity, authenticity and permanence of the scholarly record and agrees that the version of the Article that appears or will appear in the journal and embodies all value-adding publisher activities (including peer review co-ordination, copy-editing, formatting, (if relevant) pagination, and online enrichment) shall be the definitive final record of published research.

Each author further acknowledges and agrees that nothing in this License Agreement shall be deemed to permit redundant/duplicate publication of the Article in violation of publishing ethics principles, as further described below.

Author's grant of rights in the Article

Each author hereby grants to Elsevier Ltd the following rights, effective from the date on which the Article is accepted for publication:

- a. the non-exclusive right to publish, reproduce, display, distribute and otherwise use the Article, or any part of the Article, for any purpose, in print, electronic and all other media (whether now known or later developed), and to prepare derivative works, in any form, in all languages, throughout the world, for the full term of copyright;
- b. the non-exclusive right to license third parties to exercise all or any of the rights granted herein for non-commercial purposes;
- c. the exclusive right to license third parties to exercise all or any of the rights granted herein for commercial purposes; and
- d. the right to enforce the rights granted herein against third parties.

In addition, each author has selected the Creative Commons Attribution-Noncommercial Works 4.0 International License ("the CC BY-NC License") and grants Elsevier Ltd the right to apply the CC BY-NC License to the Article where the Article is published in the journal on Elsevier Ltd's and/or the publisher's online platforms on an Open Access basis. Full details of the CC BY-NC License are available at <https://creativecommons.org/licenses/by-nc/4.0/>.

Supplemental Materials and Research Data

"Supplemental Materials" shall mean materials published as a supplemental part of the Article, including but not limited to graphical, illustrative, video and audio material.

"Research Data" shall mean the result of observations or experimentation that validate research findings and that are published separate to the Article, which can include but are not limited to raw data, processed data, software, algorithms, protocols and methods.

With respect to any Supplemental Materials and/or Research Data that an author submits, that author retains all rights in such Supplemental Materials and/or Research Data and hereby grants Elsevier Ltd a perpetual worldwide, non-exclusive right and license to publish, extract, reformat, adapt, build upon, index, redistribute, link to and otherwise use all or any part of the Supplemental Materials and/or Research Data in all forms and media (whether now known or later developed), and permit others to do so.

Where Elsevier Ltd and/or the publisher publish the Article on their online platforms on an Open Access basis and publish the Supplemental Materials with the Article, Elsevier Ltd and/or the publisher shall apply the same end user license to the Supplemental Materials as to the Article. Where an author has selected a specific end user license under which the Research Data is to be made available on a site or through a service, Elsevier Ltd and/or the publisher shall apply that end user license to the Research Data on that site or service.

Reversion of rights

Articles may sometimes be accepted for publication but later rejected in the publication process, even in some cases after public posting in "Articles in Press" form, in which case all rights granted to Elsevier Ltd under this License Agreement will revert to the author (see <https://www.elsevier.com/about/policies-and-standards/article-withdrawal>).

Revisions and addenda

This License Agreement may not be varied unless such variation is in writing and signed by Elsevier Ltd and the corresponding author. This License Agreement supersedes any previous agreements entered into between each author and Elsevier Ltd in relation to the Article from the date hereof.

Author Representations/Ethics and Disclosure

Each author affirms the Author Representations noted below and confirm that they have reviewed and complied with the relevant Instructions to Authors, Ethics in Publishing policy, Declarations of Interest disclosure, and information for authors from countries affected by sanctions. Please note that some journals may require that all co-authors sign and submit Declarations of Interest disclosure forms. Each author is also aware of Elsevier Ltd's and/or the publisher's policies with respect to retractions and withdrawal (<https://www.elsevier.com/about/policies-and-standards/article-withdrawal>). For further information see the publishing ethics page at <http://www.elsevier.com/publishingethics> and the journal home page. For further information on sanctions, see: <https://www.elsevier.com/about/policies-and-standards/trade-sanctions>.

Author Representations

- The Article submitted to the journal for review is original, has been written by the stated authors and has not been previously published.
- The Article was not submitted for review to another journal while under review by this journal and will not be submitted to any other journal.
- The Article, the Supplemental Materials and the Research Data do not infringe any copyright, violate any other intellectual property, privacy or other rights of any person or entity, or contain any libelous or other unlawful matter.
- All necessary written permissions have been obtained from the copyright owners of any excerpts from copyrighted works that are included in the Article, the Supplemental Materials, and/or the Research Data, and all such third parties have been correctly and appropriately credited.
- Except as expressly set out in this License Agreement, the stated author(s) are the legal and beneficial owners of the rights granted herein and the Article is not subject to any prior rights or licenses which conflict with the terms of this License Agreement.
- Each author confirms that they are not identified as a Specially Designated National ("SDN") and if any of the authors reside in Russia, Belarus, Iran, Cuba or Syria the Article has been prepared in a personal, academic or research capacity and not as an official representative or otherwise on behalf of the relevant government or institution.
- If any personal details or images of patients, research subjects or other individuals have been used, all written and fully informed consents required by applicable law have been obtained and evidence of such consents has been retained, and the authors have complied with Elsevier Ltd's and/or the publisher's policies relating to the use of such materials. See <https://www.elsevier.com/about/policies-and-standards/patient-consent> for further information.
- Any software contained in the Supplemental Materials and/or the Research Data is free from viruses, contaminants and worms.

Corresponding Author's Representation

If the Article or any of the Supplemental Materials, or the Research Data, were prepared jointly with other authors, I (as corresponding author) have informed all co-author(s) of the terms of this License Agreement and have duly obtained their authorization to sign this License Agreement as their agent.

Governing Law and Jurisdiction

This License Agreement will be governed by and construed in accordance with the laws of the country or state in which Elsevier Ltd is incorporated ("the Governing State"), without regard to conflict of law principles, and the parties irrevocably consent to the exclusive jurisdiction of the courts of the Governing State.

☒ I have read and agree to the terms of the License Agreement.

All content on this website: Copyright © 2025 Elsevier B.V., its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

